Nichols & Pratt Advisers LLP MA Sells 205 Shares of Johnson & Johnson (NYSE:JNJ)

Nichols & Pratt Advisers LLP MA cut its stake in Johnson & Johnson (NYSE:JNJ) by 0.0% during the 1st quarter, HoldingsChannel reports. The fund owned 502,497 shares of the company’s stock after selling 205 shares during the period. Johnson & Johnson comprises 5.7% of Nichols & Pratt Advisers LLP MA’s portfolio, making the stock its 3rd largest position. Nichols & Pratt Advisers LLP MA’s holdings in Johnson & Johnson were worth $82,977,000 at the end of the most recent quarter.

Several other institutional investors have also recently added to or reduced their stakes in the stock. Harel Insurance Investments & Financial Services Ltd. raised its stake in Johnson & Johnson by 38.6% during the first quarter. Harel Insurance Investments & Financial Services Ltd. now owns 718 shares of the company’s stock valued at $119,000 after buying an additional 200 shares in the last quarter. IFM Investors Pty Ltd raised its position in shares of Johnson & Johnson by 7.2% during the 1st quarter. IFM Investors Pty Ltd now owns 486,648 shares of the company’s stock valued at $78,866,000 after acquiring an additional 32,749 shares in the last quarter. GF Fund Management CO. LTD. raised its position in shares of Johnson & Johnson by 5.1% during the 1st quarter. GF Fund Management CO. LTD. now owns 63,449 shares of the company’s stock valued at $10,522,000 after acquiring an additional 3,101 shares in the last quarter. OneDigital Investment Advisors LLC raised its position in shares of Johnson & Johnson by 1.1% during the 1st quarter. OneDigital Investment Advisors LLC now owns 87,424 shares of the company’s stock valued at $14,498,000 after acquiring an additional 916 shares in the last quarter. Finally, 44 Wealth Management LLC raised its position in shares of Johnson & Johnson by 1.4% during the 1st quarter. 44 Wealth Management LLC now owns 18,269 shares of the company’s stock valued at $3,030,000 after acquiring an additional 260 shares in the last quarter. 69.55% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

JNJ has been the topic of a number of research reports. The Goldman Sachs Group raised shares of Johnson & Johnson from a “neutral” rating to a “buy” rating and increased their target price for the stock from $157.00 to $172.00 in a report on Wednesday, April 9th. Leerink Partnrs lowered shares of Johnson & Johnson from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, May 13th. Bank of America dropped their price objective on shares of Johnson & Johnson from $171.00 to $159.00 and set a “neutral” rating on the stock in a research note on Thursday, April 10th. Barclays dropped their target price on Johnson & Johnson from $166.00 to $165.00 and set an “equal weight” rating on the stock in a research report on Thursday, April 17th. Finally, Guggenheim reaffirmed a “neutral” rating on shares of Johnson & Johnson in a research report on Wednesday, April 2nd. Eleven research analysts have rated the stock with a hold rating, seven have issued a buy rating and three have issued a strong buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $170.88.

Johnson & Johnson Price Performance

NYSE JNJ opened at $155.90 on Friday. Johnson & Johnson has a 12 month low of $140.68 and a 12 month high of $169.99. The company has a debt-to-equity ratio of 0.49, a current ratio of 1.26 and a quick ratio of 1.03. The firm has a market capitalization of $375.11 billion, a PE ratio of 17.34, a P/E/G ratio of 2.36 and a beta of 0.41. The company’s 50 day simple moving average is $153.68 and its 200 day simple moving average is $154.09.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Tuesday, April 15th. The company reported $2.77 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.59 by $0.18. The company had revenue of $21.89 billion for the quarter, compared to analysts’ expectations of $21.65 billion. Johnson & Johnson had a return on equity of 33.46% and a net margin of 24.42%. As a group, equities research analysts forecast that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, June 10th. Stockholders of record on Tuesday, May 27th were paid a $1.30 dividend. The ex-dividend date was Tuesday, May 27th. This represents a $5.20 annualized dividend and a dividend yield of 3.34%. This is a boost from Johnson & Johnson’s previous quarterly dividend of $1.24. Johnson & Johnson’s payout ratio is currently 57.84%.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.